BIOTECHNOLOGY company Aravax has announced two additions to its board of directors: former CEO of ALK-Abello, Carsten Hellmann and former CCO of Aimmune Therapeutics, Andrew Oxtoby.
The company has facilities in Australia, Europe, the UK and US, and specialises in next-generation, disease-modifying immunotherapies for food allergy.
Hellmann and Oxtoby bring many years and a depth of experience from the pharma industry, specifically in the allergy therapeutics field.
Aravax CEO Dr Pascal Hickey welcomed the new directors, and said, "These appointments represent big steps towards preparing Aravax for Phase 3 and beyond as we look forward to the results of Phase 2 trials in our lead program, PVX108 for the treatment of peanut allergy."
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Apr 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Apr 26
